Related Experiment Videos
The need for an iterative process for assessing economic outcomes associated with SSRIs.
T L Skaer1, D A Sclar, L M Robison
1Pharmacoeconomics and Pharmacoepidemiology Research Unit, College of Pharmacy, Washington State University, Pullman, Washington, USA. skaer@mail.wsu.edu
Pharmacoeconomics
|January 9, 2001
Summary
Selective serotonin reuptake inhibitors (SSRIs) offer effective depression treatment. Evaluating antidepressant pharmacotherapy requires multiple study designs to demonstrate clinical and financial value for money.
Area of Science:
- Pharmacoeconomics
- Clinical Pharmacy
- Health Services Research
Background:
- Selective serotonin reuptuptake inhibitors (SSRIs) have emerged as alternatives to tricyclic antidepressants.
- Healthcare systems globally face cost-containment pressures, necessitating value-for-money evaluations for pharmacotherapies.
- Demonstrating measurable health and financial outcomes is crucial for justifying medication expenditure.
Purpose of the Study:
- To evaluate the strengths and weaknesses of five study designs for assessing financial outcomes of antidepressant pharmacotherapy.
- To propose an iterative process for economic appraisal of pharmacotherapies from development to post-marketing phases.
- To synthesize evidence on the value for money of SSRIs in depression treatment.
Main Methods:
- Review and comparison of five study designs: randomized controlled trials (RCTs), meta-analyses, decision-analytical models (DAMs), retrospective database investigations, and randomized naturalistic inquiry.
- Analysis of how each design contributes to understanding safety, efficacy, and effectiveness.
- Emphasis on the role of post-marketing studies (database reviews, naturalistic inquiry) in assessing real-world financial merits.
Main Results:
- No single study design is sufficient for comprehensive economic appraisal of pharmacotherapy.
- An iterative approach, combining developmental and post-marketing evidence, is necessary to build a robust portfolio of data.
- Retrospective database investigations and naturalistic inquiry offer valuable insights into clinical practice patterns and financial benefits.
Conclusions:
- The first-line use of SSRIs for depression is clinically justified.
- SSRIs represent a cost-effective treatment option, demonstrating value for money in the management of depressive illness.
- A comprehensive evidence portfolio is essential for informed pharmacoeconomic decision-making.